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Abstract 
Background: Peripartum cardiomyopathy and 
doxorubicin-induced cardiomyopathy are well 
described conditions but there is little description 
in the literature of both occurring together. 
Case: A 29 year old G1P0 with a remote history 
of childhood chondroblastic osteosarcoma 
treated with high-dose doxorubicin therapy who 
developed minimally symptomatic 
cardiomyopathy during her pregnancy with 
ejection fraction reaching as low as 20-30%. 
She delivered via primary low-transverse 
cesarean section at 37 weeks complicated by 
uterine atony with an unremarkable recovery. 
Cardiomyopathy was treated with metoprolol 
and enalapril and she achieved ejection fraction 
of 44% at one year follow-up with complete 
return to baseline activity. 
Discussion: We present a woman with a history 
of doxorubicin therapy who developed 
peripartum cardiomyopathy and recovered 
symptomatically after one year. Although 
treatment of peripartum cardiomyopathy 
regardless of etiology is well-defined, there are 
few reports and no standard guidelines for 
special considerations in pregnant women with a 
history of doxorubicin therapy, a topic that may 
warrant further investigation. 
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Peripartum cardiomyopathy and 
doxorubicin-induced cardiomyopathy 
are well-described conditions, but the 
pathophysiology of both is uncertain. 
Current management strategies for 
patients with cardiomyopathy who are 
contemplating pregnancy are based on 
the type of cardiomyopathy and not 
necessarily the etiology. To this end, 
there exists a plethora of literature on 
the management of heart failure with 
reduced ejection fraction in pregnancy. 
Recent data indicates peripartum 
cardiomyopathy affects roughly 1 in 
1000 pregnancies worldwide with lower 
incidences in the United States.1 
Meanwhile, the incidence of 
doxorubicin-induced cardiotoxicity is 3-
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4% in patients who received a 
cumulative dose of 450 mg/m2 or 
greater.2 However, there is minimal 
literature and no standard guidelines 
addressing pregnancy considerations 
for patients with a history of doxorubicin 
therapy. We report a case of 
cardiomyopathy in the peripartum period 
in a patient with a remote history of 
doxorubicin therapy for childhood 
chondroblastic osteosarcoma. 
Case Report 
A 29 year-old G1P0 white female 
presented to University of Iowa 
Hospitals & Clinics (UIHC) at 12 weeks 
gestation for an obstetric consultation 
regarding her history of osteosarcoma of 
the hip. In 1995, at age seven, she 
underwent a right hip disarticulation with 
complete removal of her right lower 
extremity to treat chondroblastic 
osteosarcoma and received doxorubicin 
chemotherapy (total dose 364 mg/m2). 
She achieved full remission after this 
treatment with no subsequent 
recurrences and demonstrated sufficient 
mobility after her disarticulation with the 
use of crutches. 
At the time of her initial obstetric 
consultation, she underwent an 
echocardiogram which showed a normal 
ejection fraction (EF) of 55%. She 
continued care at an outside hospital 
until 31 weeks gestation when her local 
physician noted changes on a repeat 
echocardiogram and transferred her 
obstetric care to UIHC, a tertiary care 
center. The patient was evaluated by 
the cardiology service; the 
echocardiogram performed as part of 
this consultation showed an EF of 50%. 
At this time she endorsed shortness of 
breath though this symptom was 
attributed to pregnancy as she was able 
to move up four flights of stairs without 
discomfort. Other symptoms of heart 
failure were denied.  
At 37 weeks gestation, the patient 
presented to UIHC for routine cardiology 
and obstetric care visits; lower extremity 
edema was documented, but also noted 
to be “stable” suggesting it had been 
present previously. She denied any 
exertional shortness of breath, 
orthopnea, or paroxysmal nocturnal 
dyspnea. She remained active at full 
term, still utilizing stairs without change 
in symptoms. Vital signs during these 
visits included mild tachycardia (107 
beats per minute) and a blood pressure 
135/95, slightly higher than her baseline 
of 110s/60s. On physical exam, 
cardiovascular, respiratory and 
abdominal examinations were benign. 
Her left leg showed 2+ non-pitting 
edema with good peripheral pulses. 
Hemoglobin was 11.8, white blood cell 
count was 9.9k and urinalysis was 
normal. Differential diagnoses 
considered included preeclampsia, 
peripartum cardiomyopathy likely 
compounded by a history of doxorubicin 
therapy, acute myocardial infarction, 
and pulmonary edema. At this time, an 
echocardiogram suggested an EF of 20-
30% by visualization; these EF 
measurements were confirmed by 
transthoracic echocardiogram (TTE). 
There was evidence of left ventricular 
global hypokinesis and the ratio of early 
mitral inflow velocity to mitral annular 
early diastolic velocity (E/E’) was 15, 
which predicts an elevated left 
ventricular (LV) filling pressure. Left 
ventricular internal diameter (LVID) 
measured to 3.9 cm. Given this rapid 
decline in left ventricular function, the 
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team opted to proceed with induction of 
labor within 24 hours. 
The patient was admitted to UIHC Labor 
& Delivery; in addition to routine labor 
monitoring, maternal telemetry was 
utilized during induction until 24 hours 
postpartum. Efforts to minimize excess 
fluid overload were employed including 
strict measurement of fluid intake and 
output. Induction of labor was 
prolonged; regional anesthesia was a 
spinal block in an effort to minimize 
blood pressure alterations. Due to the 
duration of induction and maternal 
exhaustion in the second stage of labor, 
a vacuum-assisted vaginal delivery was 
unsuccessful, and she underwent a 
primary low transverse cesarean 
section. The surgery was complicated 
by uterine atony treated with rectal 
misoprostol 1000 mcg, intramuscular 
(IM) carboprost and IM intrauterine 
oxytocin. The patient did well and was 
transferred to the cardiovascular 
intensive care unit (CVICU) for 48 hours 
of monitoring after delivery. Her 
recovery was unremarkable during this 
time. Medical management of heart 
failure had been initiated with metoprolol 
12.5 mg twice daily and enalapril 2.5 mg 
once daily. She was subsequently 
transferred to the mother-baby care unit 
and was discharged home on post-
operative day four meeting all post-
operative goals.  
The patient returned to clinic one week 
after discharge with no symptoms of 
heart failure and an improving EF of 
35%. Her heart failure medications were 
titrated up and she was instructed to 
monitor her blood pressures at home. 
The patient was also counseled about 
the significant risks of future pregnancy. 
She agreed to consider use of an 
intrauterine device for contraception in 
follow-up with her local provider and 
planned to use condoms in the interim. 
Subsequent follow-up at three months 
postpartum included a TTE 
demonstrating an EF of 35% based on 
visual estimate and no regional wall 
abnormalities. One year follow-up TTE 
showed an EF of 40-45% based on 
visual estimate. Cardiac MRI at that time 
showed an EF of 44% and no evidence 
of regional wall motion abnormalities, 
cardiac ischemia, infiltration, or scarring. 
Her medications were changed to 
metoprolol 25 mg daily and enalapril 2.5 
daily. The patient did not have a 
documented form of contraception at 
that visit, but she denied symptoms of 
cardiomyopathy and her baby was 
noted to be healthy. 
Discussion 
Defined as cardiac failure in the last 
month of pregnancy or within five 
months of delivery without pre-existing 
cardiac dysfunction and no recognized 
cause of cardiomyopathy, peripartum 
cardiomyopathy (PPCM) is a well 
described pathophysiologic condition 
associated with pregnancy. The 
incidence of PPCM is estimated to be 
one in 3,186 live births; risk factors 
include advanced maternal age, 
preeclampsia, gestational hypertension, 
multiparity, and African American race.3 
Doxorubicin is a potent and efficacious 
chemotherapeutic agent used in the 
treatment of multiple forms of cancer, 
including osteosarcoma. Use of 
doxorubicin is often limited by 
cardiotoxic side effects.  
Doxorubicin cardiotoxicity in the 
peripartum period is described in only a 
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few case reports. This may be due in 
part to the effects of chemotherapeutic 
agents on fertility in general. Systemic 
chemotherapy with multiple agents is 
used for patients with high-grade 
sarcoma and carries a risk of delayed 
fertility issues, although this is more 
common in males than females.4  
Doxorubicin has been included in the 
chemotherapeutic combination for 
osteosarcoma since the 1970’s and 
contributed to a dramatic improvement 
in prognosis for patients with localized 
osteosarcoma. Long-term survival rates 
improved from 20% to 65%.5 
Doxorubicin cardiotoxicity is dose 
dependent and mechanistically related 
to protein processing, hyper-activated 
immune responses, impaired cardiac 
repair and decreased vasculogenesis.6 
The standard cumulative doxorubicin 
dose used in the United States to treat 
osteosarcoma is up to 450 mg/m2. This 
dose is associated with acute 
cardiomyopathy during chemotherapy, 
late cardiomyopathy sometimes delayed 
by decades as well as death. After 300 
to 450 mg/m2 of doxorubicin therapy, 
more than 25% of patients experience 
left ventricular systolic dysfunction 
beyond 15 years of follow-up and 
remain at risk for cardiac deterioration 
for the rest of their lives.4  
There have been a few other case 
reports published on peripartum 
cardiomyopathy associated with 
doxorubicin therapy. A 1997 case report 
narrates the case of a 28 year old 
primigravid woman who developed 
congestive heart failure 3 months after 
delivery with a history of doxorubicin 
therapy 10 years previously. The 
authors discuss the significance of the 
cumulative dose of doxorubicin.7 
Similarly, in a 2016 case report from 
Belgrade, Serbia, a 30-year-old woman 
with a history of doxorubicin 
chemotherapy for acute myelogenous 
leukemia became pregnant five years 
after achieving remission. This patient 
had an uneventful first pregnancy and 
vaginal delivery. She became pregnant 
again seven months after her prior 
delivery and developed heart failure one 
week after delivery by cesarean with an 
EF of 15%. She was treated with 
dobutamine, unfractionated and low-
molecular-weight heparin, diuretics, 
cardiotonics, beta-blockers and 
antiplatelet therapy for six weeks. Her 
EF improved to 25-30% by the time of 
discharge. Two years later, she 
continued to be asymptomatic 
considering her history of heart failure 
with an EF of 54%.8 This patient’s 
presentation of cardiomyopathy after 
two pregnancies in close proximity 
supports the hypothesis that pregnancy 
and doxorubicin cardiotoxicity cause a 
synergistically toxic effect on cardiac 
function. 
Prior to pregnancy, our patient had 
normal cardiac functioning with no 
symptoms of cardiac failure. In fact, 
throughout her pregnancy, the only 
definite sign of her deteriorating cardiac 
function was a declining EF. Her 
symptoms included mild shortness of 
breath and lower extremity edema which 
could also have been routinely attributed 
to pregnancy. It is possible that the 
increased cardiovascular load 
attributable to normal physiologic 
alterations in pregnancy further 
exacerbated an underlying left 
ventricular dysfunction caused by her 
remote therapy with cardiotoxic 
doxorubicin. 
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A retrospective cohort study of female 
cancer survivors was published in the 
Journal of Cancer Survivorship in 2016. 
The study included 847 female cancer 
survivors treated at St. Jude Children’s 
Research Hospital from 1963 to 2006 to 
see how many developed 
cardiomyopathy and whether there was 
an association with pregnancy. In this 
study, only three of the 847 female 
cancer survivors who achieved a 
cumulative 1554 live-birth pregnancies 
developed pregnancy-associated 
cardiomyopathy. Forty of these female 
cancer survivors developed non-
pregnancy associated cardiomyopathy. 
Overall, only 5% of 847 patients 
developed any form of cardiomyopathy. 
Of these 40 patients, only eight had 
deteriorated cardiac function during 
pregnancy.9  
In this group of eight, one patient 
received doxorubicin therapy at seven 
years of age with full remission and 
normal cardiac function. Similar to our 
patient, this patient developed 
cardiomyopathy in the third trimester of 
pregnancy and subsequently had a 
normal delivery with full recovery from 
the cardiomyopathy in 6 months. The 
study also found patients who 
developed cardiomyopathy had received 
higher doses of anthracyclines, 
including doxorubicin and daunorubicin, 
than those who did not develop 
cardiomyopathy.9 Patients in the study 
who developed cardiomyopathy had 
median dose of anthracyclines of 321 
mg/m2. Our patient followed this trend 
with a total dose of 364 mg/m2 of 
doxorubicin therapy.   
Regardless of the etiology of our 
patient’s cardiomyopathy, the 
management of PPCM is usually similar 
to standard treatment for heart failure of 
other etiologies, although no 
randomized clinical trials have been 
done to evaluate this treatment 
approach in PPCM.10 The goals of 
treating heart failure are to improve 
hemodynamic status, minimize signs 
and symptoms, and optimize long-term 
outcomes. Therapeutic emphasis is on 
reducing preload and afterload while 
increasing cardiac inotropy. Vasodilators 
like hydralazine and nitrates, which are 
safe during pregnancy, are used to 
achieve preload reduction. In the 
postpartum period, angiotensin-
converting enzyme inhibitors (ACE-I) 
are the mainstay of treatment for 
afterload reduction but are teratogenic 
and therefore contraindicated during 
pregnancy.11,12 Beta adrenergic 
antagonists such as extended release 
metoprolol and carvedilol are 
recommended in the postpartum period 
for women who continue to have signs 
of heart failure as well as 
echocardiographic evidence of 
ventricular compromise after more than 
two weeks of therapy.13 In the 
peripartum setting, additional 
considerations must be made for fetal 
safety as well as excretion of drugs or 
metabolites during breastfeeding.13  
The National Institutes of Health 
recommendations for peripartum 
cardiomyopathy stress the importance 
of interprofessional collaboration among 
providers including obstetricians, 
cardiologists, and neonatologists.13 
Conventional non-pharmaceutical 
therapies include limiting dietary sodium 
two grams per day and restricting fluid 
intake to two liters per day. Participation 
in daily light activity, such as walking, is 
encouraged.11  
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Our patient had been following 
recommendations for regular activity 
and was receiving care at a tertiary care 
facility with coordination between the 
Obstetric and Cardiology Departments. 
The patient’s blood pressure was in the 
normal obstetric range and she did not 
complain of symptoms of heart failure, 
therefore medications were not initiated 
in the antepartum period. She was 
started on metoprolol and enalapril 
postpartum for a persistently low EF. 
Following cesarean delivery, care was 
taken to minimize fluid shifts including 
use of intramuscular, instead of 
intravenous, oxytocin. She was 
monitored in the CVICU after delivery 
because the first 24 hours postpartum 
carry the most risk to develop 
complications of cardiomyopathy. 
Digoxin and anticoagulation are other 
common therapies for PPCM, but were 
not given to our patient because she did 
not demonstrate an arrhythmia as a 
symptom of heart failure and her EF 
improved after delivery. Currently, 
anticoagulation therapy is only indicated 
when left ventricular function is less than 
35%. Furthermore, patients who 
develop any degree of PPCM should be 
strongly advised to avoid future 
pregnancy as mortality risk is 
approximately 55%.14  
Conclusion 
In conclusion, PPCM is a rare, serious 
complication of pregnancy. Although the 
pathophysiology is unknown, it is 
important to remain vigilant for signs 
and symptoms and to employ an 
especially low threshold of suspicion in 
patients with a history of doxorubicin 
chemotherapy. With early recognition 
and therapy, prognosis for PPCM is 
generally good in the majority of cases. 
The first three months postpartum is an 
initial high risk period with 25-50% of 
women dying; meticulous surveillance is 
necessary during this time.15 However, 
in a 2005 study of 123 women with 
cardiomyopathy during or after 
pregnancy, 54% of patients achieved 
normalization of left ventricular systolic 
function at two years, an outcome that 
was more likely if the EF at diagnosis 
was more than 30%.16 Patients who 
receive doxorubicin therapy should 
receive counseling regarding cardiotoxic 
effects that could manifest during 
pregnancy. While there is minimal 
literature on the pregnancy 
considerations for patients with a history 
of doxorubicin therapy, the treatment 
recommendations for any 
cardiomyopathy, regardless of etiology, 
in pregnancy is clear and well-studied. 
The authors thank Dr. Benjamin Miller and Dr. 
Kimberly Delcour for technical assistance and 
academic discussion. 
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